Neurogene Inc. - 8-K Filing
Neurogene Inc. announced the completion of dosing in its Embolden™ registrational trial for NGN-401, a gene therapy candidate for Rett syndrome, with 25 participants enrolled (exceeding an initial target of 20). Dosing was completed by June 8, 2026. The company reported that NGN-401 has been generally well-tolerated at the 1E15 vg dose and plans to release additional interim data in mid-2026 with top-line results expected in late 2027. (Items: 7.01 and Exhibits 99)
Tickers: $NGNE